Clinical Research Workshop: Advancing Research Frameworks in MetALD, Part 1—Key Strategies for Refining Risk and Integrating Biomarkers

Nov 10 2025
Convention Center: Room 207, Level 2
2:00 PM - 3:30 PM

World Class Speakers

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
Presenter

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD

Indiana University School of Medicine
Maja Thiele, MD
Presenter

Maja Thiele, MD

Odense University Hospital
Meena B Bansal, MD, FAASLD
Presenter

Meena B Bansal, MD, FAASLD

Icahn School of Medicine at Mount Sinai (ISMMS)
Michael R Lucey, MD, FAASLD
Presenter

Michael R Lucey, MD, FAASLD

University of Wisconsin School of Medicine and Public Health

Description

Join experts providing a comprehensive overview of MetALD, ie, combined metabolic dysfunction-associated and alcohol-associated liver disease. Presenters highlight key considerations for developing robust research programs; leveraging biomarkers and omics technologies; and understanding the interplay between alcohol use, metabolic dysfunction, and liver disease progression. Speakers discuss emerging insights into risk stratification, cohort development, and the relationship between MetALD and HCC. The workshop aims to integrate translational and clinical research approaches, equipping attendees with knowledge to enhance precision medicine strategies in MetALD.

Journey Maps

Presentations

2:00 PM - 2:18 PM
Nov 10 2025
Washington, D.C.

Biomarkers and Omics in MetALD: Leveraging Emerging Tools for Risk Stratification

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD, Presenter
ALD
Liver Cancer
2:18 PM - 2:36 PM
Nov 10 2025
Washington, D.C.

Alcohol and Liver Disease: Synergistic Insights and Measuring Risk

Maja Thiele, MD, Presenter
ALD
Liver Cancer
2:36 PM - 2:54 PM
Nov 10 2025
Washington, D.C.

Defining Metabolic Parameters for Refining Risk in MetALD

Meena B Bansal, MD, FAASLD, Presenter
ALD
Liver Cancer
3:12 PM - 3:30 PM
Nov 10 2025
Washington, D.C.

MetALD: Opportunities for Future Research

Michael R Lucey, MD, FAASLD, Presenter
ALD
Liver Cancer

Objectives

  • Identify critical considerations and translational strategies for developing a MetALD research program, including biomarkers and cohort designs.
  • Describe the roles of metabolic dysfunction and alcohol use in liver disease progression and their combined impact on outcomes such as HCC.
  • Apply knowledge of emerging biomarkers and omics technologies to improve risk stratification and precision medicine in MetALD.
Chair

George Cholankeril, MD, MSECR

Baylor College of Medicine
Chair

Stephanie Rutledge, MD, MB BCh, BAO, MRCPI

Weill Cornell Medicine